Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS
Sign Up to like & getrecommendations! Published in 2025 at "Blood Advances"
DOI: 10.1182/bloodadvances.2025016229
Abstract: Key Points • In the phase 3 SELECT-MDS-1 trial, CR was similar between arms in pts with higher-risk MDS.• RARA gene overexpression/RARα activation in myeloid malignancies warrants further investigation as biomarker-driven studies are feasible. read more here.
Keywords: higher risk; phase; pivotal results; select mds ... See more keywords